Novel approach to cancer drug given £2.8 million

A way of switching off the development and growth of certain cancer cells has been identified by scientists at ProXara Biotechnology Limited, a spin out company from the University of Bristol, UK.
Results to date have proved so positive that the team now plans to develop the drug compound to a point at which it would be close to entering clinical trials, using funding of £2.8 million from the Wellcome Trust's Seeding Drug Discovery initiative.

more at http://www.bristol.ac.uk/news/2007/5243.html